EQL Pharma AB (publ) (STO: EQL)

Market Cap	2.32B
Revenue (ttm)	316.38M
Net Income (ttm)	31.18M
Shares Out	29.06M
EPS (ttm)	1.07
PE Ratio	74.57
Forward PE	33.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,473
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	32.10 - 77.00
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 5, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2023, EQL Pharma AB's revenue was 264.17 million, an increase of 1.64% compared to the previous year's 259.91 million. Earnings were 22.71 million, a decrease of -26.57%.